Understand the source comparison
IGF-1 LR3 vs Other Fat Loss Peptides: Research Comparison
Research applications exploring fat loss mechanisms often compare IGF-1 LR3 to other peptides with metabolic effects. The table below contrasts IGF-1 LR3 with three commonly studied alternatives. IGF-1 LR3 IGF-1 receptor agonism Direct HSL activation in adipoc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research applications exploring fat loss mechanisms often compare IGF-1 LR3 to other peptides with metabolic effects. The table below contrasts IGF-1 LR3 with three commonly studied alternatives.
- IGF-1 LR3
- IGF-1 receptor agonism
- Direct HSL activation in adipocytes
- Once daily
- Moderate to high (requires carb timing)
- Most direct lipolytic effect but demands glucose monitoring. Not suitable for very-low-carb protocols
- CJC-1295/Ipamorelin
- Growth hormone secretagogue
- Indirect lipolysis via elevated GH
- 1–2x daily
- Low
- Slower onset, less direct mechanism, but safer metabolic profile for extended research periods
- Tesofensine
- Monoamine reuptake inhibitor
- CNS-mediated appetite suppression + thermogenesis
- Primarily appetite-driven rather than direct adipocyte signaling. Effective but mechanism differs entirely
- AOD-9604
- Modified GH fragment (176-191)
- Mimics GH lipolytic region without receptor binding
- Very low
- Lacks the anabolic signaling of IGF-1 LR3, purely catabolic in adipose tissue. Research shows inconsistent replication of results